Navigation Links
ACS Announces $57 Million Contract With Missouri HealthNet
Date:3/7/2008

t enable patients, physicians, and pharmacists to access information that will help MO HealthNet Division improve health outcomes, facilitate coordination of care between providers, reduce dangerous drug interactions, minimize duplicate therapies, and reduce unnecessary costs. ACS will also provide Retrospective Drug Utilization Review and federal reporting services using CyberFormance(SM), a fourth component of ACS' EHR suite of web tools.

ACS is a national leader in state healthcare program administration, offering a full spectrum of systems and complementary services through an integrated solution. From care management solutions and child health programs to pharmacy benefits management and traditional Medicaid fiscal agent services, ACS has a proven track record and extensive program management expertise. ACS is also a pioneer in fraud and abuse protection and other cost containment methodologies, and is known for its collaborative approach to client relationships that produce results over the long term. ACS supports more than 23 million program recipients and processes nearly 550 million Medicaid healthcare claims annually, representing close to $50 billion in provider payments. As the nation's largest government program pharmacy benefits administrator, ACS serves 28 states, the District of Columbia and the Department of Labor with drug expenditures totaling more than $13 billion.

For more information about ACS' EHR solutions and ACS' experience in Missouri, please visit http://www.acs-inc.com/informedhealth.

ACS, a global FORTUNE 500 company with 62,000 people supporting client operations reaching more than 100 countries, provides business process outsourcing and information technology solutions to world-class commercial and government clients. The company's Class A common stock trades on the New York Stock Exchange under the symbol "ACS." Learn more about ACS at

SOURCE Affiliated Computer Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Nfocus Neuromedical Announces Acquisition of StarFire Medical
2. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Cancer Indexes
3. Pharos Innovations Announces First Recipient of National Award for Achievements in Chronic Care Programs and Research
4. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
5. The Hain Celestial Group Announces the Acquisition of MaraNatha(R) and SunSpire(R) Brands
6. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
7. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
8. Milestone Scientific Announces Chicago Dental Societys 143rd Midwinter Meeting Proved Successful
9. Zounds Hearing Enters Moorestown and Announces $225,000 Hearing Partnership With Twilight Wish Foundation
10. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
11. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...n Eye Care Hospitals, one of the largest eye care ...its first branch here, with seven more in the offi...boration with K. Premraj, a prominent ophthalmic s...r of Prems' Eye Clinic. The first facility would h...
...on Americans have hypertension, that is, blood pre...n 120/80 mmHg). If untreated, it can lead to heart...anges are the first-stage treatment for the diseas...rescribed. Many patients with high blood pressure...
..., Dr Mukesh Haikerwal, today launched a unique web...//suffering fatigue, and make hospitals safer for ...Assessment website allows doctors to track their w...ng hours over a week, and determine whether their ...
...ent research published in The Lancet states that, ...y could help in faster information processing and ...emonstrated the effects of reduced levels of folat...omocysteine, in the blood of older adults which re...
Other Medicine News:Health News:Chinese Herb Shows Promise In Reducing Hypertension 2Health News:New AMA Tool Empowers Doctors to Work Safer Hours 2
(Date:10/8/2008)...ment in patients with pulmonary arterial hype...ve limited benefit for this debilitating, rap...e, -- Imatinib mesylate, available as Gleevec(R...inhibit protein associated with PAH, -- Novarti...e in PAH in 2009 EAST HANOVER, N.J., Oct. 8 ...
(Date:10/7/2008)...exas Cardiac Arrhythmia,Institute (TCAI) at St. Da...nly a few sites in the nation to participate in an...reat persistent atrial fibrillation. TCAI, an,inte...specializing in heart,rhythm disorders, is a partn...s Cardiovascular Consultants., "This is just anot...
(Date:10/7/2008)...-- CEL-SCI Corporation,(NYSE: CVM ) announced tod...reement (MTA) with the National Institutes of Heal...r. Francesco M. Marincola, M.D., to,investigate th...ironment,caused by CEL-SCI,s cancer drug Multikine...ease and Immunogentics Section, Department of Tran...
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
Breaking Medicine Technology:Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4Finding the source 3A Cells that initiate a common infant tumor identified 21225 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 2Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 3Impact of Rising Gas Food Prices Felt Globally 21221 1Impact of Rising Gas Food Prices Felt Globally 21221 2Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 1Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 2
... ONCONASE for,Treatment of Neuroblastoma, BLOOMFIE...Alfacell Corporation today announced that new data... is active against naive and,chemoresistant neurob...vivo data published in Cancer,Letters (2007; Vol. ...ween Alfacell and Martin Michaelis, M.D., Ph.D., a...
...p; CEO of the Lupus,Foundation of America, Inc., W...- The Lupus,Foundation of America, Inc. and more t...iting the preliminary findings of the Phase,III cl...nt for,lupus kidney disease being tested by Asprev...ments for lupus patients is,critical because many ...
Other Medicine Technology:In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 2In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 3Lupus Foundation of America Statement on Results for Clinical Study,of CellCept Released by Aspreva Pharmaceutical Company 2
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
Medicine Products: